Year All 2026 2025 2024 2023 2021 Oct 14, 2026 Iambic Announces Pricing of Initial Public Offering Read More Oct 05, 2026 Iambic Submits IND for a Potentially Brain-Penetrant KIF18A Inhibitor IAM217, Its Second Wholly Owned AI-Discovered Candidate Read More Sep 21, 2026 Iambic Launches Enchant v3 – Molecular Superintelligence Designed to Advance End-to-End Drug Discovery & Development Read More Sep 21, 2026 AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery Read More Jun 22, 2026 Bayer and Iambic collaborate to advance drug discovery with AI Read More May 19, 2026 Iambic Named to CNBC Disruptor 50 for Second Consecutive Year Read More May 11, 2026 Iambic to participate in upcoming investor conferences Read More Apr 02, 2026 Iambic to Participate in April Investor Conferences Read More Mar 02, 2026 Iambic to Participate in March Investor Conferences Read More Feb 09, 2026 Iambic Announces Collaboration with Takeda to Advance AI-Driven Design of Small Molecules Read More
Oct 05, 2026 Iambic Submits IND for a Potentially Brain-Penetrant KIF18A Inhibitor IAM217, Its Second Wholly Owned AI-Discovered Candidate Read More
Sep 21, 2026 Iambic Launches Enchant v3 – Molecular Superintelligence Designed to Advance End-to-End Drug Discovery & Development Read More
Sep 21, 2026 AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery Read More
Feb 09, 2026 Iambic Announces Collaboration with Takeda to Advance AI-Driven Design of Small Molecules Read More
